SynthesisScientific reports2026
Isolated para-aortic lymph node recurrence from colorectal cancer treated by radiotherapy: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Optimal management for isolated para-aortic lymph node (PALN) recurrence from colorectal cancer (CRC) remains undefined. We evaluated the efficacy and safety of radiotherapy (RT) for this indication. A PRISMA-compliant systematic review and meta-analysis (PROSPERO CRD42025634494) was conducted using four databases through April 2025. Pooled locoregional progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were estimated using a random-effects model. Five retrospective studies (n = 220) were included. Pooled 1- and 3-year LPFS were 84% (95% CI, 78-89%) and 69% (62-76%), respectively. Pooled 1- and 3-year PFS were 54% (42-65%) and 22% (14-32%). Pooled 1- and 3-year OS were 91% (87-95%) and 64% (54-73%). Primary colon tumors were associated with poorer survival outcomes, while female sex predicted improved 3-year PFS. Severe (grade ≥ 3) acute and chronic toxicities were low (7.7% and 0.5%, respectively). Modern RT for PALN recurrence from CRC provides favorable local control with acceptable toxicity. With a 3-year OS of 64%, RT offers a potential survival benefit for carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.